Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $23.00.

Several research firms have commented on ARCT. Wall Street Zen upgraded Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd.

Arcturus Therapeutics Stock Down 5.2%

Shares of NASDAQ ARCT opened at $13.98 on Friday. The company’s 50-day simple moving average is $9.42 and its 200-day simple moving average is $8.28. Arcturus Therapeutics has a 52-week low of $5.50 and a 52-week high of $24.17. The firm has a market cap of $397.31 million, a price-to-earnings ratio of -4.22 and a beta of 2.48.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.16. The firm had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. Equities research analysts anticipate that Arcturus Therapeutics will post -3.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Arcturus Therapeutics during the second quarter worth about $17,566,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Arcturus Therapeutics by 12.9% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after acquiring an additional 262,347 shares during the last quarter. Heartland Advisors Inc. acquired a new stake in Arcturus Therapeutics in the 2nd quarter valued at about $1,474,000. Hsbc Holdings PLC purchased a new position in Arcturus Therapeutics in the 2nd quarter worth approximately $394,000. Finally, Amova Asset Management Americas Inc. lifted its stake in Arcturus Therapeutics by 12.9% in the 1st quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after purchasing an additional 262,347 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.